KR20210158420A - 항-cd137 항체 - Google Patents

항-cd137 항체 Download PDF

Info

Publication number
KR20210158420A
KR20210158420A KR1020217041897A KR20217041897A KR20210158420A KR 20210158420 A KR20210158420 A KR 20210158420A KR 1020217041897 A KR1020217041897 A KR 1020217041897A KR 20217041897 A KR20217041897 A KR 20217041897A KR 20210158420 A KR20210158420 A KR 20210158420A
Authority
KR
South Korea
Prior art keywords
cancer
seq
antibody
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217041897A
Other languages
English (en)
Korean (ko)
Inventor
크리스토퍼 칼 프라이
마이클 드웨인 칼로스
헬렌 코타나이즈
스테파니 린 샌디퍼
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20210158420A publication Critical patent/KR20210158420A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L7/00—Arrangements for synchronising receiver with transmitter
    • H04L7/04—Speed or phase control by synchronisation signals
    • H04L7/10—Arrangements for initial synchronisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B10/00—Transmission systems employing electromagnetic waves other than radio-waves, e.g. infrared, visible or ultraviolet light, or employing corpuscular radiation, e.g. quantum communication
    • H04B10/25—Arrangements specific to fibre transmission
    • H04B10/2575—Radio-over-fibre, e.g. radio frequency signal modulated onto an optical carrier
    • H04B10/25752—Optical arrangements for wireless networks
    • H04B10/25753—Distribution optical network, e.g. between a base station and a plurality of remote units

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020217041897A 2017-08-01 2018-07-25 항-cd137 항체 Ceased KR20210158420A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762539687P 2017-08-01 2017-08-01
US62/539,687 2017-08-01
PCT/US2018/043632 WO2019027754A1 (en) 2017-08-01 2018-07-25 ANTI-CD137 ANTIBODIES
KR1020207002814A KR102344620B1 (ko) 2017-08-01 2018-07-25 항-cd137 항체

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207002814A Division KR102344620B1 (ko) 2017-08-01 2018-07-25 항-cd137 항체

Publications (1)

Publication Number Publication Date
KR20210158420A true KR20210158420A (ko) 2021-12-30

Family

ID=63165504

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217041897A Ceased KR20210158420A (ko) 2017-08-01 2018-07-25 항-cd137 항체
KR1020207002814A Active KR102344620B1 (ko) 2017-08-01 2018-07-25 항-cd137 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207002814A Active KR102344620B1 (ko) 2017-08-01 2018-07-25 항-cd137 항체

Country Status (25)

Country Link
US (3) US10906983B2 (https=)
EP (2) EP3661544B1 (https=)
JP (2) JP6743320B1 (https=)
KR (2) KR20210158420A (https=)
CN (1) CN111182919B (https=)
AU (2) AU2018311804B2 (https=)
BR (1) BR112020001441A2 (https=)
CA (2) CA3071383C (https=)
CL (1) CL2020000233A1 (https=)
CO (1) CO2020001050A2 (https=)
CR (1) CR20200042A (https=)
DO (1) DOP2020000020A (https=)
EA (1) EA202090204A1 (https=)
EC (1) ECSP20007663A (https=)
ES (1) ES2912651T3 (https=)
IL (1) IL272349B2 (https=)
JO (1) JOP20200016B1 (https=)
MA (1) MA49749A (https=)
MX (1) MX2020001351A (https=)
PE (1) PE20200839A1 (https=)
PH (1) PH12020500225A1 (https=)
SA (1) SA520411186B1 (https=)
SG (1) SG11202000747VA (https=)
UA (1) UA128388C2 (https=)
WO (1) WO2019027754A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250104655A (ko) 2023-12-29 2025-07-08 쿠팡 주식회사 옵션 피커 화면 제공 방법 및 그 장치
KR20250104669A (ko) 2023-12-29 2025-07-08 쿠팡 주식회사 옵션 선택 가이드 정보 제공 방법 및 그 장치
KR20250132789A (ko) 2024-02-29 2025-09-05 쿠팡 주식회사 옵션 피커 화면 제공 방법 및 그 장치

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018301393B2 (en) 2017-07-11 2025-02-27 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
CA3071383C (en) * 2017-08-01 2022-04-12 Eli Lilly And Company Anti-cd137 antibodies
US11512134B2 (en) 2017-08-01 2022-11-29 Eli Lilly And Company Anti-CD137 antibodies
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
US20210054089A1 (en) * 2018-03-23 2021-02-25 Eli Lilly And Company Anti-cd137 antibodies for combination with anti-pd-1 antibodies
JP7059388B2 (ja) * 2018-03-23 2022-04-25 イーライ リリー アンド カンパニー 抗ｐｄ－ｌ１抗体との組み合わせのための抗ｃｄ１３７抗体
JP7090204B2 (ja) * 2018-07-19 2022-06-23 イーライ リリー アンド カンパニー 免疫チェックポイントを標的とする二重特異性抗体
CN112739339B (zh) 2018-07-23 2024-12-27 海德堡医药研究有限责任公司 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途
KR102259473B1 (ko) 2018-08-10 2021-06-02 추가이 세이야쿠 가부시키가이샤 항cd137 항원 결합 분자 및 그의 사용
NZ781538A (en) 2019-04-24 2025-12-19 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
CN120441704A (zh) 2019-06-26 2025-08-08 圆祥生技股份有限公司 T细胞活化抗体
TWI895351B (zh) * 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
JP2024501127A (ja) 2020-11-25 2024-01-11 上海君賽生物科技有限公司 腫瘍浸潤リンパ球培地及びその使用
WO2024179465A1 (zh) 2023-02-27 2024-09-06 上海君赛生物科技有限公司 表达膜结合细胞因子的肿瘤浸润淋巴细胞

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
RU2192281C2 (ru) 1996-10-11 2002-11-10 Бристол-Маерс Сквибб Компани Способы и композиции для иммуномодуляции
US7651686B2 (en) 2001-10-09 2010-01-26 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
MX337040B (es) * 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
US10899840B2 (en) 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
EP3183269A2 (en) 2014-08-22 2017-06-28 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
KR20180016972A (ko) * 2015-02-22 2018-02-20 소렌토 쎄라퓨틱스, 인코포레이티드 Cd137에 결합하는 항체 치료제
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
GB201619648D0 (en) * 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
CA3071383C (en) * 2017-08-01 2022-04-12 Eli Lilly And Company Anti-cd137 antibodies

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250104655A (ko) 2023-12-29 2025-07-08 쿠팡 주식회사 옵션 피커 화면 제공 방법 및 그 장치
KR20250104669A (ko) 2023-12-29 2025-07-08 쿠팡 주식회사 옵션 선택 가이드 정보 제공 방법 및 그 장치
KR20250132789A (ko) 2024-02-29 2025-09-05 쿠팡 주식회사 옵션 피커 화면 제공 방법 및 그 장치

Also Published As

Publication number Publication date
SA520411186B1 (ar) 2025-06-29
US20260109775A1 (en) 2026-04-23
CO2020001050A2 (es) 2020-02-18
US20230279134A1 (en) 2023-09-07
CA3146758A1 (en) 2019-02-07
ECSP20007663A (es) 2020-06-30
JOP20200016A1 (ar) 2020-01-28
CR20200042A (es) 2020-03-03
DOP2020000020A (es) 2020-02-28
UA128388C2 (uk) 2024-07-03
AU2021277707A1 (en) 2021-12-23
JP2020182492A (ja) 2020-11-12
CA3071383C (en) 2022-04-12
IL272349B2 (en) 2024-09-01
IL272349B1 (en) 2024-05-01
JP7257364B2 (ja) 2023-04-13
KR20200023439A (ko) 2020-03-04
EP3661544A1 (en) 2020-06-10
CN111182919B (zh) 2023-07-07
MX2020001351A (es) 2020-03-09
US12453771B2 (en) 2025-10-28
JP6743320B1 (ja) 2020-08-19
BR112020001441A2 (pt) 2020-08-04
EP3661544B1 (en) 2022-04-13
MA49749A (fr) 2021-03-24
CN111182919A (zh) 2020-05-19
US20200377607A1 (en) 2020-12-03
US10906983B2 (en) 2021-02-02
JOP20200016B1 (ar) 2022-10-30
JP2020527356A (ja) 2020-09-10
PH12020500225A1 (en) 2020-11-09
PE20200839A1 (es) 2020-08-13
CL2020000233A1 (es) 2020-07-31
EA202090204A1 (ru) 2020-05-22
NZ761548A (en) 2024-07-05
WO2019027754A1 (en) 2019-02-07
CA3071383A1 (en) 2019-02-07
SG11202000747VA (en) 2020-02-27
ES2912651T3 (es) 2022-05-26
KR102344620B1 (ko) 2022-01-03
AU2018311804A1 (en) 2020-02-13
EP4070811A1 (en) 2022-10-12
AU2018311804B2 (en) 2021-09-02
IL272349A (en) 2020-03-31

Similar Documents

Publication Publication Date Title
KR102344620B1 (ko) 항-cd137 항체
US12590150B2 (en) Antibody against Nectin-4 and application thereof
KR101601387B1 (ko) c-KIT 항체 및 이의 용도
KR102352670B1 (ko) 항-N3pGlu 아밀로이드 베타 펩티드 항체 및 그의 용도
KR102949202B1 (ko) 항-btn3a 항체 및 암 또는 감염성 질환의 치료에서 이들의 용도
CN100455598C (zh) 功能人源化抗人cd20抗体及其应用
KR20240017090A (ko) 항-pd-1 항체와의 조합을 위한 항-cd137 항체
KR102432046B1 (ko) 항-pd-l1 항체와의 조합을 위한 항-cd137 항체
CN114728171A (zh) 抗tigit抗体及其应用
US11512134B2 (en) Anti-CD137 antibodies
RU2800726C2 (ru) Антитела против btn3a и их применение при лечении рака или инфекционных заболеваний
HK40081907A (en) Anti-cd137 antibodies
HK40074348A (zh) 抗tigit抗体及其应用
KR20260053570A (ko) 항-btn3a 항체 및 암 또는 감염성 질환의 치료에서 이들의 용도
HK40019208B (en) Anti-cd137 antibodies
EA043217B1 (ru) Анти-cd137 антитела

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20211221

Application number text: 1020207002814

Filing date: 20200129

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220120

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220202

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220927

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220202

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I